Depigmented and polymerised house dust mite allergoid: Allergen content, induction of IgG4 and clinical response

International Archives of Allergy and Immunology

Volumn 153, Issue 1, 2010, Pages 61-69

  Gallego, M T ^a   Iraola, V ^a   Himly, M ^d   Robinson, D S ^a   Badiola, C ^b   Garcia Robaina J C ^c   Briza, P ^d   Carnes J ^a  

^a Research and Development Department   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^d UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Allergens; Allergic asthma; Depigmented and polymerised extracts; IgG4; Mites; Sequencing allergens

Indexed keywords

CORTICOSTEROID; DEPIGOID; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ANTIBODY TITER; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; LIQUID CHROMATOGRAPHY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NONHUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS;

ADOLESCENT; ADULT; ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; CONJUNCTIVITIS, ALLERGIC; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PLANT EXTRACTS; PYROGLYPHIDAE; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950045625     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000301580     Document Type: Article

References (32)

1. Bousquet J, Lockey RF, Malling HJ: WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53(suppl 44):1-42. (Pubitemid 28346358)
2. Malling HJ: Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53: 461-472.
3. Nelson HS: Allergen immunotherapy: where is it now? J Allergy Clin Immunol 2007; 119: 769-779.
4. Grammer LC, Shaughnessy MA, Patterson R: Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1985; 76: 397-401.
5. Casanovas M, Fernández-Caldas E, Alamar R, Basomba A: Comparative study of tolerance between unmodified and high doses of chemically modified allergen vaccines of Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 2005; 137: 211-218.
6. Kahlert H, Grage-Griebenow E, Stüwe HT, Cromwell O, Fiebig H: T cell reactivity with allergoids: influence of the type of APC. J Immunol 2000; 165: 1807-1815.
7. Kalinski P, Lebre MC, Kramer D, Jong EC, van Schijndel JWPM, Kapsenberg ML: Analysis of the CD4+ T cell responses to house dust mite allergoid. Allergy 2003; 58: 648-656.
8. Alvarez-Cuesta E, Aragoneses-Gilsanz E, Martin-Garcia C, Berges-Gimeno P, Gonzalez-Mancebo E, Cuesta-Herranz J: Immunotherapy with depigmented glutaraldehydepolymerised extracts: changes in quality of life. Clin Exp Allergy 2005; 35: 572-578.
9. Colas C, Monzon S, Venturini M, Lezaun A: Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. J Allergy Clin Immunol 2006; 117: 810-816.
10. García-Robaina JC, Sánchez I, de la Torre F, Fernández-Caldas E, Casanovas M: Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006; 118: 1026-1032.
11. Ameal A, Vega-Chicote JM, Fernandez S, Miranda A, Carmona MJ, Rondon MC, et al: Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005; 60: 1178-1183.
12. Guerra F, Daza JC, Almeda E: Immunotherapy with a depigmented, polymerised vaccine of Olea europaea pollen allergens significantly reduces specific bronchial and skin test reactivity in sensitized patients after one year of treatment. J Investig Allergol Clin Immunol 2003; 13: 108-117.
13. Carnes J, Himly M, Gallego MT, Iraola V, Robinson DS, Fernández-Caldas E, Briza P: Detection of allergen composition and in vivo immunogenicity of depigmented allergoids of Betula alba. Clin Exp Allergy 2009; 39: 426-434.
14. Reuter A, Lüttkopf D, Vieths S: New frontiers in allergen standardization. Clin Exp Allergy 2009; 39: 307-309.
15. Berrens L: A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use. European Patent No EP0662080B1; 1997.
16. Casanovas M, Marañón F, Bel I: Comparison of skin-prick test assay and reverse enzyme immunoassay competition (REINA-C) for biological activity of allergens. Clin Exp Allergy 1994; 24: 134-139.
17. Bairoch A, Apweiler R, Wu CH, Barker WC, Boeckmann B, Ferro S, et al: The Universal Protein Resource (UniProt). Nucleic Acids Res 2005; 33(database issue):D154-D159.
18. Mastrandrea F, Serio G, Minardi A, et al: IgE responses to Dermatophagoides pteronyssinus native major allergens Der p 1 and Der p 2 during long-term specific immunotherapy. Allergy 1997; 52: 1115-1119.
19. Lund L, Henmar H, Würtzen PA, Lund G, Hjortskov N, Larsen JN: Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy. Clin Exp Allergy 2007; 37: 564-571.
20. Dormann D, Ebner C, Jarman ER, Montermann E, Kraft D, Reske-Kunz AB: Responses of human birch pollen allergen-reactive T cells to chemically modified allergens (allergoids). Clin Exp Allergy 1998; 28: 1374-1383.
21. Till SJ, Francis JN, Nouri-Aria K, Durham SR: Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113: 1025-1034.
22. Akdis CA, Blaser K: Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol 2000; 121: 261-269.
23. Bussmann C, Maintz L, Hart J, Allam JP, Vrtala S, Chen KW, et al: Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007; 37: 1277-1285.
24. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J: Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990; 85: 460-472.
25. Nanda A, O'Connor M, Anand M, Dreskin SC, Zhang L, Hines B, et al: Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004; 114: 1339-1344.
26. Hedlin G, Graff-Lonnevig V, Heilborn H, Lilja G, Norrlind K, Pegelow KO, et al: Immunotherapy with cat-and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study. J Allergy Clin Immunol 1986; 77: 488-496. (Pubitemid 16135702)
27. Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, Till SJ: Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121: 1120-1125.
28. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW: A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990; 86: 521-531.
29. Casanovas M, Martín R, Jiménez C, Caballero R, Fernández-Caldas E: Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerised allergen extracts. Clin Exp Allergy 2007; 37: 434-440.
30. Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy Study Group: Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 319-325.
31. Purohit A, Niederberger V, Kronqvist M, Horak F, Grönneberg R, Suck R, et al: Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008; 38: 1514-1525.
32. Oldfield WL, Larché M, Kay AB: Effect of Tcell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360: 47-53.